Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma

CAR-T cell expansion CAR-T cell therapy Lymphomas Neoplasia Non-Hodgkin lymphoma Transplant-related toxicity Stem cell transplantation Molecular biology Digital droplet PCR Diffuse large B-cell lymphoma Immune effector cell-associated neurotoxicity syndrome

Journal

Turkish journal of haematology : official journal of Turkish Society of Haematology
ISSN: 1308-5263
Titre abrégé: Turk J Haematol
Pays: Turkey
ID NLM: 9606065

Informations de publication

Date de publication:
31 08 2023
Historique:
medline: 1 9 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell) therapy. However, it remains unclear whether CAR-T cell expression itself is clinically relevant. We assessed CAR-T cell mRNA expression and DNA concentration by digital droplet PCR in peripheral blood from 14 sequential CAR-T cell recipients. Patients were grouped according to CAR-T cell peak expression. Patients with high CAR-T cell peak expression (8 patients; 57%) had higher rates of ICANS (p=0.0308) and intensive care unit admission (p=0.0404), longer durations of hospitalization (p=0.0077), and, although not statistically significant, a higher rate of CRS (p=0.0778). There was a correlation of CAR-T cell mRNA expression with DNA concentration, but CAR-T cell expression levels failed to correlate to response or survival. Our data suggest that higher CAR-T cell peak mRNA expression is associated with increased risk for ICANS and possibly CRS, requiring further investigation in larger studies. Sitokin salımı sendromu (CRS) ve immün efektör hücre ile ilişkili nörotoksisite sendromu (ICANS), kimerik antijen reseptörü T-hücresi (CAR-T hücresi) tedavisi gören nüksetmiş/refrakter diffüz büyük B-hücreli lenfoma hastalarında önemli komplikasyonlardır. Bununla birlikte, CAR-T hücre ifadesinin klinikle ilişkili olup olmadığı belirsizliğini korumaktadır. Ondört CAR-T hücre alıcısından periferik kanda dijital damlacık PCR’ı ile CAR-T hücresi mRNA ekspresyonunu ve DNA konsantrasyonunu değerlendirdik. Hastalar, CAR-T hücre pik ifadesine göre gruplandırıldı. Yüksek CAR-T hücre pik ekspresyonu olan hastalar (8 hasta; %57) daha yüksek ICANS (p=0,0308) ve yoğun bakıma yatış (p=0,0404), daha uzun hastanede yatış süreleri (p=0,0077) ve istatistiksel olarak anlamlı olmasa da, daha yüksek CRS oranına sahipti (p=0,0778). CAR-T hücresi mRNA ekspresyonu ile DNA konsantrasyonu arasında bir korelasyon vardı, ancak CAR-T hücresi ekspresyon seviyeleri, yanıt veya hayatta kalma ile korelasyon göstermedi. Verilerimiz, daha yüksek CAR-T hücre zirvesi mRNA ekspresyonunun, daha büyük çalışmalarda daha fazla araştırmayı gerektiren, artan ICANS ve muhtemelen CRS riski ile ilişkili olduğunu göstermektedir.

Autres résumés

Type: Publisher (tur)
Sitokin salımı sendromu (CRS) ve immün efektör hücre ile ilişkili nörotoksisite sendromu (ICANS), kimerik antijen reseptörü T-hücresi (CAR-T hücresi) tedavisi gören nüksetmiş/refrakter diffüz büyük B-hücreli lenfoma hastalarında önemli komplikasyonlardır. Bununla birlikte, CAR-T hücre ifadesinin klinikle ilişkili olup olmadığı belirsizliğini korumaktadır. Ondört CAR-T hücre alıcısından periferik kanda dijital damlacık PCR’ı ile CAR-T hücresi mRNA ekspresyonunu ve DNA konsantrasyonunu değerlendirdik. Hastalar, CAR-T hücre pik ifadesine göre gruplandırıldı. Yüksek CAR-T hücre pik ekspresyonu olan hastalar (8 hasta; %57) daha yüksek ICANS (p=0,0308) ve yoğun bakıma yatış (p=0,0404), daha uzun hastanede yatış süreleri (p=0,0077) ve istatistiksel olarak anlamlı olmasa da, daha yüksek CRS oranına sahipti (p=0,0778). CAR-T hücresi mRNA ekspresyonu ile DNA konsantrasyonu arasında bir korelasyon vardı, ancak CAR-T hücresi ekspresyon seviyeleri, yanıt veya hayatta kalma ile korelasyon göstermedi. Verilerimiz, daha yüksek CAR-T hücre zirvesi mRNA ekspresyonunun, daha büyük çalışmalarda daha fazla araştırmayı gerektiren, artan ICANS ve muhtemelen CRS riski ile ilişkili olduğunu göstermektedir.

Identifiants

pubmed: 37519105
doi: 10.4274/tjh.galenos.2023.2023.0136
pmc: PMC10476258
doi:

Substances chimiques

cell-associated neurotoxicity 0
Receptors, Chimeric Antigen 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-196

Informations de copyright

©Copyright 2023 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.

Déclaration de conflit d'intérêts

Conflict of Interest: No conflict of interest was declared by the authors.

Références

Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Exp Hematol. 2020 Aug;88:7-14.e3
pubmed: 32673688
Oncologist. 2020 Oct;25(10):894-902
pubmed: 32339368
Crit Care Explor. 2021 Oct 11;3(10):e0552
pubmed: 34651139
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Mediterr J Hematol Infect Dis. 2021 Jan 01;13(1):e2021012
pubmed: 33489051
Clin Cancer Res. 2019 Feb 15;25(4):1142-1146
pubmed: 30309857
Hematol Oncol. 2021 Feb;39(1):97-104
pubmed: 32979278
Cytotherapy. 2018 Dec;20(12):1415-1418
pubmed: 30385043
Pathology. 2018 Jan;50(1):74-87
pubmed: 29167021
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321
pubmed: 31446199
Blood Adv. 2021 Jul 27;5(14):2799-2806
pubmed: 34264268
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Hematol Oncol. 2018 Sep 24;11(1):121
pubmed: 30249264
Oncologist. 2020 Feb;25(2):e321-e327
pubmed: 32043764
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Wien Klin Wochenschr. 2021 Dec;133(23-24):1318-1325
pubmed: 34613477
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Blood Adv. 2020 Feb 11;4(3):560-572
pubmed: 32045475
Cancer Discov. 2018 Aug;8(8):958-971
pubmed: 29880584
Biomark Res. 2018 Jan 22;6:4
pubmed: 29387417
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797

Auteurs

Christian Messerli (C)

University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland

Gertrud Wiedemann (G)

University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland

Naomi Porret (N)

University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland

Michael Nagler (M)

University Institute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland

Katja Seipel (K)

University of Bern, Department for Biomedical Research, Bern, Switzerland

Barbara Jeker (B)

University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland

Urban Novak (U)

University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland

Sacha Zeerleder (S)

University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland

Ulrike Bacher (U)

University Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland

Thomas Pabst (T)

University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH